Results 151 to 160 of about 262,207 (307)
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Molecular Oncology, EarlyView.Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source
Purification and characterization of native bovine milk plasminogen activators
, 1992 The breakdown of milk proteins by proteases affects the quality of dairy products. The proteolysis results in changes in bovine milk viscosity, solubility, cheesemaking characteristics, cheese ripening and age gelation of UHT milk.
Lu, Dongjin David
core +1 more source
Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer
Molecular Oncology, EarlyView.Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley +1 more source
Molecular Oncology, EarlyView.RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner +14 more
wiley +1 more source
, 2014 The first example of the readily scalable direct allylic alkylation of azlactones with simple allylic alcohols has been developed, which is catalyzed by Pd(PPh3)(4) alone in the absence of any activators under neutral conditions.
Liu, MW (Liu, Muwen) +5 more
core
Molecular Oncology, EarlyView.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
Molecular Oncology, EarlyView.This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
Adenosine monophosphate-activated protein kinase activation is associated with suppression of NLRP3 inflammasome-mediated neuroinflammation in a weight-drop model of traumatic brain injury in Sprague-Dawley rats. [PDF]
Animal Model Exp MedKodi T +3 more
europepmc +1 more source
Understanding and exploiting MmyB-like transcriptional activators [PDF]
One of the biggest ongoing challenges facing society and healthcare in the present is the prevalence of antimicrobial resistance. Novel sources of antibiotics are needed desperately to combat this crisis. A potential supply for this could spring from the
Robertshaw, Daniel
core
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source